About GSK SYLVER 221971
This app has been created exclusively for participants in the medical study for GSK SYLVER 221971. It contains Televisit functionality and allows participants to complete questionnaires.
A Phase 1/2 Master Protocol to Assess the Safety and Efficacy of DNA-Damage Repair Inhibitors, as Monotherapies or in Combination with Other Anti-Cancer Agents in Adult Participants with Solid Tumors (SYLVER).
A Phase 1/2 Master Protocol to Assess the Safety and Efficacy of DNA-Damage Repair Inhibitors, as Monotherapies or in Combination with Other Anti-Cancer Agents in Adult Participants with Solid Tumors (SYLVER).
GSK SYLVER 221971 Screenshots
Tap to Rate:
